← All trials
NCT05049603
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Sep 20, 2021
- Last posted
- Sep 20, 2021
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PisaLead sponsor
- University of MessinaCollaborator
- University of InsubriaCollaborator
- University of PisaReponsible party - principal investigator
- University of CataniaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.